A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

2021101 citationsJournal Articlehybrid Open Access

Authors

Yusuf Yazıcı · New York University

T.E. McAlindon · Tufts Medical Center

Allan Gibofsky · Cornell University

Nancy E. Lane · University of California, Davis

Christian Lattermann · University of Kentucky

Nebojša Skrepnik · Tucson Orthopaedic Institute

C.J. Swearingen ·

Abstract

This 24-week Phase 2b trial demonstrated the efficacy of LOR on PROs in knee OA subjects. The optimal dose for future studies was identified as 0.07 mg LOR.

Topics & Keywords

Osteoarthritis Treatment and Mechanisms Knee injuries and reconstruction techniques Tendon Structure and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Osteoarthritis and Cartilage

Volume 29, Issue 5, pp. 654-666

DOI: 10.1016/j.joca.2021.02.004

Field-Weighted Citation Impact: 12.60